

## PLATELETS Pooled or Apheresis

OTHER NAMES	Pooled platelets, LR CPD = Pooled random donor platelets Apheresis platelets = Single donor platelets			
PRODUCT COMPOSITION	<ul> <li>CPD Platelets, Pooled, LR are produced from CPD whole blood collections from which the buffy coat layer is separated. The buffy coat layers from 4 donations are pooled together with the plasma from one of the original donations. The pooled platelet concentrate is then filtered to reduce the number of leukocytes. A typical unit of CPD Platelets, Pooled, LR contains at least 240 x 10<sup>9</sup> platelets suspended in 300 mL of plasma.</li> <li>Platelets Apheresis, LR are collected from single donors. The typical unit of Platelets Apheresis, LR contains at least 300 x 10<sup>9</sup> platelets per unit.</li> <li>Trace amounts of red blood cells are also present in some units; these will appear pink to salmon coloured.</li> <li>The Canadian Blood Services (CBS) performs bacterial testing by culture at the time of production on CPD Platelets, Pooled, LR and Platelets, Apheresis, LR.</li> </ul>			
INFORMED CONSENT	Mandatory			
ALTERNATIVES	Non-blood Product: None  Blood Product: None			
DOSAGE	The number of units of platelets to be administered depends on the clinical situation of each patient  Adult dosage: See indications:  - 1 unit CPD Platelets, Pooled, LR or  - 1 unit Platelets, Apheresis, LR  Children and Premature Infants: The usual platelet dose is 5-10mL per kg. Platelet, Apheresis, LR should be selected if possible. Older children receive approximately 5mL per kg up to 1 unit of Platelets, Apheresis, LR. This dosage would be expected to increase the platelet count of an 18kg child by about 50 x 109/L			
ADMINISTRATION	<ul> <li>Rate of infusion should be as fast as clinically tolerated         <ul> <li>Usually 1 dose given over 60 minutes</li> <li>Slow rate 2 ml/minute</li> <li>Average rate (after initial 15 minutes) 4-10 ml/minute</li> </ul> </li> <li>Use Standard Blood Administration set with 170-260 micron filter, using gravity flow</li> <li>Maximum infusion time is 4 hours</li> <li>Compatible with 0.9% NaCl</li> </ul>			
DIAGNOSTIC MONITORING	Vital sign monitoring as per hospital policy for any blood, blood component and other related product. In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.  • Response to platelet transfusion should be assessed by obtaining a 60 minute post transfusion platelet count  • The monitoring of patient response may identify patients who are refractory  • The response to platelet transfusion is best assessed by observing whether bleeding stops and by the measuring of post-transfusion platelet increments			

Page 1 of 2 Revised: June 2019



١	Н	low	VOL	want	to h	e ti	reated	

How you want to be treated.	
CLINICAL INDICATIONS	<ul> <li>Refer to Platelet (Plt) guidelines at www.pbco.ca         <ul> <li>Plt &lt;100 x 10 /L Neurosurgery, CNS trauma</li> <li>Plt &lt;50 to 80 x 10 /L Epidural Catheter insert/removal</li> <li>Plt &lt;50 x 10 /L and significant microvascular bleeding or surgery</li> <li>Plt &lt;20 x 10 /L and fever or coagulopathy</li> <li>Plt &lt;10 x 10 /L marrow failure</li> <li>Known platelet dysfunction (drug induced or hereditary) and a high risk of bleeding (ie. Post op cardiac surgery)</li> </ul> </li> <li>Platelets Apheresis, LR are usually used for patients refractory to platelets from random donor pools</li> <li>Contraindications         <ul> <li>Plasma coagulation deficits and some conditions with rapid platelet destruction</li> <li>Thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS)</li> <li>Active heparin induced thrombocytopenia (HIT)</li> </ul> </li> </ul>
SPECIAL CONSIDERATIONS	<ul> <li>Requires a Type and Screen from current admission</li> <li>ABO/Rh type and pooled/apheresis units issued by Transfusion Medicine (TM) are based on inventory availability</li> <li>Any incompatible groups will have had further testing to determine eligibility for transfusion</li> <li>Administration of RhIg may be considered in cases of transfusion of Rh positive platelets to an Rh negative recipient</li> <li>Depending on the transfusion history and/or the clinical status, cellular products may require some modification. Contact TM at 68003 for more information related to:         <ul> <li>Anti-CMV negative (7 days prior to bone marrow transplant to 99 days post)</li> <li>Irradiated (selected clinical cases only)</li> <li>Plasma removed, saline replaced</li> </ul> </li> </ul>
STORAGE CONDITIONS	<ul> <li>NOT REFRIGERATE PLATELETS</li> <li>Stored in a TM-monitored blood product storage area at 20-24°C</li> <li>Gently agitate during storage and immediately prior to transfusion</li> </ul>
REFERENCES	<ul> <li>American Association of Blood Banks, (2003) AABB Technical Manual 14<sup>th</sup> Edition</li> <li>Circular of Information, Canadian Blood Services February 2011 and www.blood.ca</li> <li>Guidelines for the Use of Platelet Transfusions. (2003) The British Journal of Haematology. (122). p 10-23.</li> <li>Harmening, D., (1989) Modern Blood Banking and Transfusion Practices, 3<sup>rd</sup> Edition. Philadelphia: F.A. Davis Company. p 18-23 &amp; 328-330.</li> </ul>

Page 2 of 2 Revised: June 2019